within Pharmacolibrary.Drugs.ATC.B;

model B03AA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03AA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ferrous aspartate is an iron salt of aspartic acid used as an oral iron supplement to treat or prevent iron deficiency anemia. It provides bioavailable iron for erythropoiesis and is generally used in patients with low iron levels. It is not widely available in all markets today and other ferrous salts are more commonly used in clinical practice.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic parameters (e.g., bioavailability, volume of distribution, clearance) for ferrous aspartate are reported in existing literature. The following are estimates based on typical values for oral ferrous iron salts in adults.</p><h4>References</h4><ol><li><p>Disch, G, et al., &amp; Schumacher, E (1996). Therapeutic availability of iron administered orally as the ferrous gluconate together with magnesium-L-aspartate hydrochloride. <i>Arzneimittel-Forschung</i> 46(3) 302–306. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8901154/\">https://pubmed.ncbi.nlm.nih.gov/8901154</a></p></li><li><p>Bednarski, M, et al., &amp; Tęsiorowski, M (2015). The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studies. <i>Pharmacological reports : PR</i> 67(3) 405–409. DOI:<a href=\"https://doi.org/10.1016/j.pharep.2014.10.019\">10.1016/j.pharep.2014.10.019</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25933945/\">https://pubmed.ncbi.nlm.nih.gov/25933945</a></p></li><li><p>Bubeck, J, et al., &amp; Classen, HG (1994). Potentiation of magnesium-deficiency-induced foetotoxicity by concomitant iron deficiency and its prevention by adequate supply via drinking water. <i>Magnesium research</i> 7(3-4) 245–254. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7786687/\">https://pubmed.ncbi.nlm.nih.gov/7786687</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03AA09;
